A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)

Completed · Phase 3 · NCT06584916

Conditions: Obesity, Overweight

Research payments reported, 2025: $8.1M
U.S. investigators named: 28
Sites paid: 26
Planned or actual enrollment: 376

About the trial

Sponsor: Eli Lilly and Company
Tested: Orforglipron (drug), Placebo (drug)
Dates: Started 2024-09-13; completion 2025-11-21
Results posted: Not yet

The main purpose of this study is to evaluate the efficacy and safety of orforglipron on maintenance of body weight reduction in participants who previously completed treatment with injectable tirzepatide (Zepbound) or injectable semaglutide (Wegovy) in the SURMOUNT-5 trial (NCT05822830).

From ClinicalTrials.gov, last updated 2026-06-04. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Eli Lilly and Company reported $8.1M in research payments for this study in 2025 (55 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.

At a glance

About the trial

Industry funding

U.S. investigators named on this study

Sites paid to run it